双相情感障碍患者的自杀死亡:死亡时的特征和治疗

IF 4.5 2区 医学 Q1 CLINICAL NEUROLOGY
Ayal Schaffer, Prudence Po Ming Chan, Vera Yu Men, Rosalie Steinberg, Rachel Hb Mitchell, Gin Malhi, Lakshmi N Yatham, Mark Sinyor
{"title":"双相情感障碍患者的自杀死亡:死亡时的特征和治疗","authors":"Ayal Schaffer, Prudence Po Ming Chan, Vera Yu Men, Rosalie Steinberg, Rachel Hb Mitchell, Gin Malhi, Lakshmi N Yatham, Mark Sinyor","doi":"10.1111/bdi.70061","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to compare suicide deaths in those with or without bipolar disorder (BD), taking into particular consideration the degree to which treatment at the time of death, according to toxicology data, reflects evidence-based pharmacotherapy.</p><p><strong>Methods: </strong>Coroner data were coded for all verified suicide deaths in the City of Toronto, Canada (1998-2020). Suicide decedents with BD (n = 340) were compared to the non-BD group (n = 4948) on demographic, clinical, and suicide-related variables. In a subsample of decedents, the presence and/or lethality of medications or substances at the time of death was identified from toxicology data and compared between groups and across time (two 11.5 year epochs). Data were analyzed using univariate analyses.</p><p><strong>Results: </strong>Several noteworthy demographic, clinical, and suicide-specific differences between BD and non-BD suicide groups emerged. Antidepressants (48.9%) and benzodiazepines (46.7%) were the most commonly present medications among people with BD, at a proportion similar to the non-BD group. There was a significant decrease in the presence of mood stabilizers across time (33.3% vs. 13.5%, p = 0.006), and lithium was present in only 5.8% of decedents with BD. Opioids (22.1%) and antipsychotics (22.1%) were the most common substances detected in lethal amounts in the BD group.</p><p><strong>Conclusions: </strong>The findings of this study suggest that a substantial proportion of people with BD who die by suicide are not receiving first-line treatments at the time of death. While causality cannot be established, further exploration of pharmacotherapy at the time of death would ideally link to living controls to address issues of risk and lethality.</p>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Suicide Deaths in People With Bipolar Disorder: Characteristics and Treatments at Time of Death.\",\"authors\":\"Ayal Schaffer, Prudence Po Ming Chan, Vera Yu Men, Rosalie Steinberg, Rachel Hb Mitchell, Gin Malhi, Lakshmi N Yatham, Mark Sinyor\",\"doi\":\"10.1111/bdi.70061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study aimed to compare suicide deaths in those with or without bipolar disorder (BD), taking into particular consideration the degree to which treatment at the time of death, according to toxicology data, reflects evidence-based pharmacotherapy.</p><p><strong>Methods: </strong>Coroner data were coded for all verified suicide deaths in the City of Toronto, Canada (1998-2020). Suicide decedents with BD (n = 340) were compared to the non-BD group (n = 4948) on demographic, clinical, and suicide-related variables. In a subsample of decedents, the presence and/or lethality of medications or substances at the time of death was identified from toxicology data and compared between groups and across time (two 11.5 year epochs). Data were analyzed using univariate analyses.</p><p><strong>Results: </strong>Several noteworthy demographic, clinical, and suicide-specific differences between BD and non-BD suicide groups emerged. Antidepressants (48.9%) and benzodiazepines (46.7%) were the most commonly present medications among people with BD, at a proportion similar to the non-BD group. There was a significant decrease in the presence of mood stabilizers across time (33.3% vs. 13.5%, p = 0.006), and lithium was present in only 5.8% of decedents with BD. Opioids (22.1%) and antipsychotics (22.1%) were the most common substances detected in lethal amounts in the BD group.</p><p><strong>Conclusions: </strong>The findings of this study suggest that a substantial proportion of people with BD who die by suicide are not receiving first-line treatments at the time of death. While causality cannot be established, further exploration of pharmacotherapy at the time of death would ideally link to living controls to address issues of risk and lethality.</p>\",\"PeriodicalId\":8959,\"journal\":{\"name\":\"Bipolar Disorders\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bipolar Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bdi.70061\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bipolar Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bdi.70061","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在比较双相情感障碍(BD)患者和非双相情感障碍患者的自杀死亡情况,根据毒理学数据,特别考虑到死亡时的治疗程度反映了循证药物治疗。方法:对加拿大多伦多市(1998-2020年)所有经证实的自杀死亡的验尸官数据进行编码。在人口学、临床和自杀相关变量方面,将患有双相障碍的自杀死亡患者(n = 340)与非双相障碍组(n = 4948)进行比较。在死者的子样本中,根据毒理学数据确定了死亡时药物或物质的存在和/或致命性,并比较了组间和时间(两个11.5年周期)。采用单变量分析对数据进行分析。结果:双相障碍和非双相障碍自杀组之间出现了几个值得注意的人口统计学、临床和自杀特异性差异。抗抑郁药(48.9%)和苯二氮卓类药物(46.7%)是双相障碍患者中最常见的药物,比例与非双相障碍组相似。随着时间的推移,情绪稳定剂的存在显著减少(33.3%对13.5%,p = 0.006),只有5.8%的双相障碍患者存在锂。在双相障碍组中,阿片类药物(22.1%)和抗精神病药物(22.1%)是最常见的致命剂量物质。结论:本研究的结果表明,相当一部分自杀的双相障碍患者在死亡时没有接受一线治疗。虽然无法确定因果关系,但在死亡时进一步探索药物治疗的理想做法是将其与生活控制联系起来,以解决风险和致命性问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Suicide Deaths in People With Bipolar Disorder: Characteristics and Treatments at Time of Death.

Objectives: This study aimed to compare suicide deaths in those with or without bipolar disorder (BD), taking into particular consideration the degree to which treatment at the time of death, according to toxicology data, reflects evidence-based pharmacotherapy.

Methods: Coroner data were coded for all verified suicide deaths in the City of Toronto, Canada (1998-2020). Suicide decedents with BD (n = 340) were compared to the non-BD group (n = 4948) on demographic, clinical, and suicide-related variables. In a subsample of decedents, the presence and/or lethality of medications or substances at the time of death was identified from toxicology data and compared between groups and across time (two 11.5 year epochs). Data were analyzed using univariate analyses.

Results: Several noteworthy demographic, clinical, and suicide-specific differences between BD and non-BD suicide groups emerged. Antidepressants (48.9%) and benzodiazepines (46.7%) were the most commonly present medications among people with BD, at a proportion similar to the non-BD group. There was a significant decrease in the presence of mood stabilizers across time (33.3% vs. 13.5%, p = 0.006), and lithium was present in only 5.8% of decedents with BD. Opioids (22.1%) and antipsychotics (22.1%) were the most common substances detected in lethal amounts in the BD group.

Conclusions: The findings of this study suggest that a substantial proportion of people with BD who die by suicide are not receiving first-line treatments at the time of death. While causality cannot be established, further exploration of pharmacotherapy at the time of death would ideally link to living controls to address issues of risk and lethality.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bipolar Disorders
Bipolar Disorders 医学-精神病学
CiteScore
8.20
自引率
7.40%
发文量
90
审稿时长
6-12 weeks
期刊介绍: Bipolar Disorders is an international journal that publishes all research of relevance for the basic mechanisms, clinical aspects, or treatment of bipolar disorders and related illnesses. It intends to provide a single international outlet for new research in this area and covers research in the following areas: biochemistry physiology neuropsychopharmacology neuroanatomy neuropathology genetics brain imaging epidemiology phenomenology clinical aspects and therapeutics of bipolar disorders Bipolar Disorders also contains papers that form the development of new therapeutic strategies for these disorders as well as papers on the topics of schizoaffective disorders, and depressive disorders as these can be cyclic disorders with areas of overlap with bipolar disorders. The journal will consider for publication submissions within the domain of: Perspectives, Research Articles, Correspondence, Clinical Corner, and Reflections. Within these there are a number of types of articles: invited editorials, debates, review articles, original articles, commentaries, letters to the editors, clinical conundrums, clinical curiosities, clinical care, and musings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信